New hope for colorectal cancer: experimental drug combo enters phase 2 trial
NCT ID NCT07662031
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding an experimental drug called tovecimig to standard chemotherapy (FOLFIRI) can shrink tumors or slow cancer growth in people with metastatic colorectal cancer who have already tried one prior treatment. The study will enroll 25 participants and measure how many respond to the treatment, as well as track side effects and survival. It is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tovecimig (CTX-009) combined with FOLFIRI chemotherapy (irinotecan, leucovorin, 5-fluorouracil)
- What this could lead to
- If successful, this could offer a new treatment option for people with metastatic colorectal cancer who have already tried one standard therapy.
- What could go wrong
- This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?